
|Articles|April 15, 2004
FDA ready to set standards for contrast sensitivity testing
The FDA soon will approve standards for contrast sensitivity testing in clinical trials. The approval is a step that will not only make the administration of this test easier for ophthalmologists but its comparison with clinical trial data and other testing centers simpler and more valuable as well.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
4
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
5















































.png)


